Alzheimer’s disease, the primary cause of dementia, has been assumed since long to originate in the brain. But a new research from the Chinese researchers and the University of British Columbia has indicated that it could be prompted by breakdowns in other parts of the body.
The findings, now published in the journal, ‘Molecular Psychiatry’ provide hope that drug therapies in the future might be able to slow down or stop the disease with affecting directly on the brain, which is a sensitive, complicated, and often is a hard to reach target. Instead, the drugs that will be developed for treating the Alzheimer’s diseases could target organs such as liver or kidney, getting rid of the blood with toxic proteins much before it reaches the brain.
The researchers showed this cancer like mobility with the help of a technique known as parabiosis. Parabiosis involves surgically attaching two samples together so that they can share the same supply of blood for numerous months.
Dr. Weihong Song, Psychiatry professor at UBC and Yan-Jian Wang, a neurology professor at Third Military Medical University in Chongqing, attached a modified mice, carrying a mutant human gene that creates high degrees of protein known as amyloid-bet, with a regular mice, which usually doesn’t develop Alzheimer’s disease. Results showed that the normal mice attached with its modified partner for one year developed Alzheimer’s disease. Researchers say that the amyloid-beta travelled from the genetically modified mice to the normal partner’s brain, where it piled up and started to cause damage.